US stocks anomaly | Liley Financial raises the target price to $26 for Novavax (NVAX.US), up more than 3%.

Zhitong Finance · Oct 10 22:58 · Ratings

On Thursday, novavax (NVAX.US) fluctuated and rose more than 5% at one point, rising over 3% as of the time of publication, closing at $13.08.

According to the Securities Times app, on Thursday, novavax (NVAX.US) fluctuated and rose more than 5% at one point, rising over 3% as of the time of publication, closing at $13.08. On the news front, Riley Financial analyst Mayank Mamtani maintained a "buy" rating on novavax and raised the target price from $23 to $26.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

美股异动 | 莱利金融上调目标价至26美元 诺瓦瓦克斯医药(NVAX.US)涨逾3%

US stocks anomaly | Liley Financial raises the target price to $26 for Novavax (NVAX.US), up more than 3%.

Risk Disclaimer

Statement

美股异动 | 莱利金融上调目标价至26美元诺瓦瓦克斯医药(NVAX.US)涨逾3%